Prognostic value of Bcl-2 in two independent populations of estrogen receptor positive breast cancer patients treated with adjuvant endocrine therapy
| Autor: | Anita Giobbie-Hurder, Karsten Bjerre, Anne E. Lykkesfeldt, Bent Ejlertsen, Katrine L Henriksen, Mathilde S. Larsen, Anne Vibeke Lænkholm, Birgitte Bruun Rasmussen |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Oncology
Pathology medicine.medical_specialty Antineoplastic Agents Hormonal Receptor ErbB-2 Population Estrogen receptor Breast Neoplasms Article Immunoenzyme Techniques Breast cancer Double-Blind Method Internal medicine medicine Carcinoma Humans Radiology Nuclear Medicine and imaging education Survival rate In Situ Hybridization Fluorescence Retrospective Studies education.field_of_study business.industry Letrozole Carcinoma Ductal Breast Hematology General Medicine Middle Aged Prognosis medicine.disease Survival Rate Tamoxifen Proto-Oncogene Proteins c-bcl-2 Receptors Estrogen Chemotherapy Adjuvant Tissue Array Analysis Immunohistochemistry Female Neoplasm Grading business medicine.drug |
| Zdroj: | Acta Oncologica. 51:781-789 |
| ISSN: | 1651-226X 0284-186X |
| Popis: | Estrogen receptor (ER) status is not an optimal marker for response to adjuvant endocrine therapy since approximately 30% of patients with ER-positive tumors eventually relapse. Bcl-2 is regulated by ER and may thus be considered as an indicator of ER activity and a candidate supplementary marker to ER status.Tumor tissue from 257 patients with ER-positive breast cancer treated with tamoxifen was used for determination of the best threshold for immunohistochemical Bcl-2 assessment as prognostic marker. Subsequently, samples from the Danish patients of the randomized clinical trial BIG 1-98 comprising 1191 ER-positive patients treated with tamoxifen, letrozole or a sequence of the two were immunohistochemically stained for Bcl-2 to further explore the prognostic value of Bcl-2.Two Bcl-2 levels were found to divide the population of the primary study into significantly different groups according to disease-free survival (DFS). Multivariate analysis confirmed the significance of the lowest level, and showed Bcl-2 to be an independent prognostic marker. Analysis of the Danish cohort of the BIG 1-98 confirmed that Bcl-2 was a significant predictor of DFS, independent of known prognostic markers. However, in an additional analysis of a subset of the Danish cohort of BIG 1-98 including only HER-2 normal patients, the effect of Bcl-2 was not statistically significant.Low Bcl-2 can predict poor outcome of patients with ER-positive tumors treated with adjuvant endocrine therapy, whereas the use of Bcl-2 for determination of addition of chemotherapy was not supported by this study. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|